Расширенный поиск

Преимущества порошковой ингаляционной системы HandiHaler® при лечении хронической обструктивной болезни легких различной тяжести

Полный текст:

Об авторах

И. В. Лещенко
Уральская государственная медицинская академия


И. И. Баранова
Клиника пульмонологии МО "Новая больница"


Список литературы

1. Global initiative for chronic obstructive pulmonary disease (GOLD). Global strategy for the diagnosis, management, and prévention of chronic obstructive pulmonary disease. NHLBI/WHO Workshop Report. Publ. № 2701. April 2001.

2. Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Bethesda: National Heart, Lung and Blood Institute. April 2001; Update of the management sections, GOLD web-site ( ). Date update: 1 Jule 2003.

3. Witek T.J., Schachter E.N. Delivery of drugs by aerosol. In Pharm acology and therapeutics in respiratory care. Philadelphia: Saunders; 1994: 31-55.

4. National Heart, Lung and Blood Institute, National Institutes of Health. International consensus reports on diagnosis and treatment of asthma. Eur. Respir. J. 1992; 5: 601-641.

5. Larsen J.S., Hahn М., Ekholm B., Wick K.A. Evaluation of conventional press-and-breathe metered-dose inhaler technique in 501 patients. J. Asthma 1994; 31: 193-199.

6. Thomson J., Irvine T.N., Grathwohl K., Roth B. Misuse of metered-dose inhalers in hospitalized patients. Chest 1994; 105: 715-717.

7. Hanania N.A., W ittman R., Kesten S., Chapman K.R. Medical personnel's knowledge of and ability to use inhaling devices: metered-dose inhalers, spacing chambers and breath-actuated dry powder inhalers. Chest 1994; 105: 111-117.

8. Kallen. Bricanyl Turbuhaler® in the treatment of asthma: a six week multi-centre study carried out in Sweden, the United Kingdom, Denmark, Norway and Finland. Eur. Respir. J. 1991; 4: 175-179.

9. Kesten S., Elias М., Girling W. et al. Patient handing of a multi-dose dry powder inhalation device for albuterol. Chest 1994; 105: 1077-1081.

10. Chrystyn H. The discus inhaler. A review of its pharmaceutical and clinical performance. Clin. D ru g Invest. 1999; 18: 403-412.

11. Srichana T ., Martin G.P., Marrio tt C. Dry powder inhalers: the influence of device resistance and powder formulation on drug and lactose deposition in vitro. Eur. J. Pharm . Sci. 1998; 7: 73-80.

12. Borgstom L.E., Bondesson F., Moren E. et al. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subject. Eur. Respir. J. 1994; 7: 69 -73.

13. Malton A ., Sumby B .S., Dandiker Y. A comparison of in vitro drug delivery from salbutamol Diskus and terbutaline Turbuhale inhalers. J. Pharm. Med. 1996; 6: 35-48.

14. Dewar M.H., Jamieson A., McLean A., Crompton G.K. Peak inspiratory flow through Turbuhaler in chronic obstructive airway disease. Respir. Med. 1999; 93: 342-344.

15. Hill L.S., Slater A.L. A comparison of the performance of two modern multidose dry powder asthma inhalers. Respir. Med. 1998; 92: 105-110.

16. Barnes P.J. The pharmacological properties of tiotropium Chest 2000; 117: 63S-66S.

17. Chodosh S., Flanders J. S., Kesten S. et al. Effective delivery of particles with the HandiHalere dry powder inhalation system over a range of Chronic Obstructive Pulmonary Disease Severity. J. Aerosol Med. 2001; 14 (3): 309-315.

18. Clark A.R., Hollingworth A.M. The relationship between powder inhaler resistance and peak inspirotary conditions in healthy volunteers — implication for in vitro testing. J. Aerosol Med. 1993; 6: 99-110.

19. Richards R., Saunders M. Need for a comparative performance standard for dry powder inhalers. Thorax 1993; 48: 1186-1187.

20. Svartengren K., Lindstad P.-A., Svartengren M. et al. Added external resistance reduces oropharyngeal deposition and increases lung deposition of aerosol particles in asthmatics. Am. J. Respir. Crit. Care Med. 1995; 152: 32-37.

21. Dahl R., Backer V., Ollgaard B. et al. Assessment of patient performance of the HandiHalera compared with the metered dose inhaler four weeks after instruction. Respir. Med. 2003; 97: 1126-1133.


Для цитирования:

Лещенко И.В., Баранова И.И. Преимущества порошковой ингаляционной системы HandiHaler® при лечении хронической обструктивной болезни легких различной тяжести. Пульмонология. 2004;(4):124-127.

For citation:

Leschenko I.V., Baranova I.I. Advantages of powdered inhalation system HandiHaler® in therapy of chronic obstructive pulmonary disease. PULMONOLOGIYA. 2004;(4):124-127. (In Russ.)

Просмотров: 28

ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)